The U.S. National Institutes of Health (NIH) announced on November 16 the appointment of Dr. John Powers III as the permanent director of the National Institute of Allergy and Infectious Diseases (NIAID). Powers, who has served as acting director since June, will oversee an annual budget of approximately $6.6 billion and lead research into infectious diseases, allergies, and immunologic issues.
The appointment follows the departure of Dr. Jeffery Taubenberger, who stepped down earlier in 2024 after serving as acting director. NIAID, which has been led by Dr. Anthony Fauci from 1984 until late 2022, funds research across academic institutions, small businesses, and operates laboratories in Maryland and Montana.
Dr. Jay Bhattacharya, NIH director, stated in a release that Powers has spent over three decades at NIAID as a physician-scientist, emphasizing his commitment to rigor, transparency, and research outcomes. Powers, who holds a medical degree from Temple University School of Medicine, has been with NIAID since 1999.
Background and Institutional Context
NIAID’s portfolio includes funding for research into emerging pathogens, vaccine development, and chronic immunologic conditions. The institute plays a central role in the U.S. response to infectious disease threats, including pandemic preparedness and antimicrobial resistance research.
The announcement comes amid ongoing scrutiny of NIAID’s past practices. In August 2024, Dr. David Morens, a former senior adviser to the NIAID director, pleaded guilty to conspiring to defraud the United States by concealing records. Morens is scheduled to be sentenced in March 2027. No charges have been filed against Fauci, despite a referral to federal prosecutors during his tenure.
Powers’ appointment marks a transition for an agency that has faced public and congressional scrutiny over its handling of the COVID-19 pandemic, funding decisions, and internal governance. His leadership will guide NIAID’s research priorities and funding allocations moving forward.